We see the strongest effect of doxorubicin with the BCL-XL inhibitor and navitoclax and think the combination of doxorubicin with navitoclax and also of tamoxifen with navitoclax could be effective treatment options in HL. This evidence concerns the gene BCL2L1 and Hodgkins lymphoma.